Lck is a key target of imatinib and dasatinib in T-cell activation

被引：71
作者：
Lee, K. C. [1 ,2 ,3 ]
Ouwehand, I. [1 ,2 ,3 ]
Giannini, A. L. [1 ,2 ,3 ]
Thomas, N. S. [4 ]
Dibb, N. J. [5 ]
Bijlmakers, M. J. [1 ,2 ,3 ]
机构：
[1] Kings Coll London, Dept Immunobiol, Sch Med, Guys Hosp, London WC2R 2LS, England
[2] Kings Coll London, Kings Coll Hosp, London WC2R 2LS, England
[3] Kings Coll London, St Thomas Hosp, London WC2R 2LS, England
[4] Kings Coll London, Dept Haematol Med, Rayne Inst, London WC2R 2LS, England
[5] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London, England
来源：
LEUKEMIA | 2010年 / 24卷 / 04期
关键词：
LYMPHOCYTES IN-VITRO; KINASE INHIBITOR; PROLIFERATION; BMS-354825;
D O I：
10.1038/leu.2010.11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：896 / 900
页数：6
相关论文
共 11 条
  • [1] The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
    Blake, Stephen
    Hughes, Timothy P.
    Mayrhofer, Graham
    Lyons, A. Bruce
    [J]. CLINICAL IMMUNOLOGY, 2008, 127 (03) : 330 - 339
  • [2] Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling
    Chen, J.
    Schmitt, A.
    Chen, B.
    Rojewski, M.
    Ruesseler, V.
    Fei, F.
    Yu, Y.
    Yu, X.
    Ringhoffer, M.
    von Harsdorf, S.
    Greiner, J.
    Goetzz, M.
    Guillaume, P.
    Doehner, H.
    Bunjes, D.
    Schmitt, M.
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2008, 12 (5B) : 2107 - 2118
  • [3] Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro
    Cwynarski, K
    Laylor, R
    Macchiarulo, E
    Goldman, J
    Lombardi, G
    Melo, JV
    Dazzi, F
    [J]. LEUKEMIA, 2004, 18 (08) : 1332 - 1339
  • [4] 2-aminothiazole as a novel kinase inhibitor template.: Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor
    Das, Jagabandhu
    Chen, Ping
    Norris, Derek
    Padmanabha, Ramesh
    Lin, James
    Moquin, Robert V.
    Shen, Zhongqi
    Cook, Lynda S.
    Doweyko, Arthur M.
    Pitt, Sidney
    Pang, Suhong
    Shen, Ding Ren
    Fang, Qiong
    de Fex, Henry F.
    McIntyre, Kim W.
    Shuster, David J.
    Gillooly, Kathleen M.
    Behnia, Kamelia
    Schieven, Gary L.
    Wityak, John
    Barrish, Joel C.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (23) : 6819 - 6832
  • [5] Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo
    Dietz, AB
    Souan, L
    Knutson, GJ
    Bulur, PA
    Litzow, MR
    Vuk-Pavlovi, S
    [J]. BLOOD, 2004, 104 (04) : 1094 - 1099
  • [6] A small molecule-kinase interaction map for clinical kinase inhibitors
    Fabian, MA
    Biggs, WH
    Treiber, DK
    Atteridge, CE
    Azimioara, MD
    Benedetti, MG
    Carter, TA
    Ciceri, P
    Edeen, PT
    Floyd, M
    Ford, JM
    Galvin, M
    Gerlach, JL
    Grotzfeld, RM
    Herrgard, S
    Insko, DE
    Insko, MA
    Lai, AG
    Lélias, JM
    Mehta, SA
    Milanov, ZV
    Velasco, AM
    Wodicka, LM
    Patel, HK
    Zarrinkar, PP
    Lockhart, DJ
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (03) : 329 - 336
  • [7] Regulation of the Src family kinase Lck by Hsp90 and ubiquitination
    Giannini, A
    Bijlmakers, MJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (13) : 5667 - 5676
  • [8] Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
    Schade, Andrew E.
    Schieven, Gary L.
    Townsend, Robert
    Jankowska, Anna M.
    Susulic, Vojkan
    Zhang, Rosemary
    Szpurka, Hadrian
    Maciejewski, Jaroslaw P.
    [J]. BLOOD, 2008, 111 (03) : 1366 - 1377
  • [9] Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
    Seggewiss, R
    Loré, K
    Greiner, E
    Magnusson, MK
    Price, DA
    Douek, DC
    Dunbar, CE
    Wiestner, A
    [J]. BLOOD, 2005, 105 (06) : 2473 - 2479
  • [10] Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
    Sillaber, C.
    Herrmann, H.
    Bennett, K.
    Rix, U.
    Baumgartner, C.
    Boehm, A.
    Herndlhofer, S.
    Tschachler, E.
    Superti-Furga, G.
    Jaeger, U.
    Valent, P.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (12) : 1098 - 1109
12